Bristol-Myers names new CEO; Keryx raising $100M;

@FierceBiotech: First on Fierce: Eyeing an IPO, Zymeworks partners up with Celgene on bispecifics. Report | Follow @FierceBiotech

@JohnCFierce: Gene therapy pioneer ReGenX fuels R&D, hiring spree with $30M VC round. Article | Follow @JohnCFierce

@DamianFierce: "Precision medicine" about to get stuffed into 100K bio PRs. "Our precision medicine immunotherapy, with applications in NASH and Ebola ..." | Follow @DamianFierce

> Bristol-Myers Squibb ($BMY) Chief Operating Officer Giovanni Caforio will take over the top spot on May 5 when CEO Lamberto Andreotti will step down and serve as executive chairman of the board. News

> Keryx Biopharmaceuticals ($KERX) is raising $100 million in a stock offering, raising cash to commercialize Auryxia, its treatment for chronic kidney disease. More

> AbbVie ($ABBV) has cut the ribbon on an R&D center on the University of Illinois campus, recruiting grad students to participate in data-minded projects. More

Medical Device News

@FierceMedDev: ICYMI yesterday: Samsung, Welch Allyn back $20M round for contact-free monitoring startup EarlySense. Article | Follow @FierceMedDev

@VarunSaxena2: Bill introduced in Congress to simplify marketing of 'research use only' devices and diagnostics. Story | Follow @VarunSaxena2

@EmilyWFierce: Abbott Labs continues Dx winning streak with bladder cancer biomarker deal. Article | Follow @EmilyWFierce

> Cheetah Medical reveals promising study results for noninvasive blood monitoring tech. News

> Hospira gets FDA nod for wireless infusion pump, finishing up two-year plan to reinvigorate devices. Story

Pharma News

@FiercePharma: Law firms trolling for shareholders to sue Sanofi over alleged kickbacks. News | Follow @FiercePharma

@CarlyHFierce: Depomed drawing on digital savvy--and 250 reps--to relaunch Nucynta franchise. Story | Follow @CarlyHFierce

> Actavis CEO: Pharma believer and Botox user, yes. The Borg? No. More

> Salix Pharmaceuticals eyeing sale in wake of corporate fallout. Article

Drug Delivery News

> Celator's delivery platform results in FDA's fast-track designation for its cancer candidate. Report

> U. Arizona team looks to bring GI delivery vehicle to market. More

> 'Micromotors' made of zinc and polymer actively release drugs at stomach lining. Story

> BD must still pay $350M+ due to safety syringe spat; other punishments delayed pending appeal. Article

> India's Piramal to buy U.S. maker of sterile injectables, antibody drug conjugates. News

Diagnostics News

> Abbott Labs continues Dx winning streak with bladder cancer biomarker deal. More

> SV Bio changes name to Lifecode, plans rollout of NGS cancer assay. Story

> Protein analysis method could act as new cancer biomarker. More

> DNA Electronics snags nanoMR for $24M to gain ground in sepsis market. Story

> GenomeDx expands prostate cancer Dx reach with Medicare coverage deal. Article

Pharma Marketing News

> Depomed drawing on digital savvy--and 250 reps--to relaunch Nucynta franchise. Story

> Embattled Salix hires bankers to weigh a potential sale. More

> J&J eyes long-acting boost for Invega franchise with quick FDA look at new formula. Report

> Lilly snares formulary spots for diabetes meds, no pricing war necessary. Story

> Eisai's copay offer on Belviq has unintended consequences for Arena. Article

Suggested Articles

No biohazardous substances were in the room where the explosion happened, according to the Russian virology center.

Merck has a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S.

Acceleron has chalked up another phase 2 flop as its pipeline thins a little more.